<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> group of acquired clonal <z:e sem="disease" ids="C0005956" disease_type="Disease or Syndrome" abbrv="">bone marrow diseases</z:e> has been captured under the term of <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) that occur predominantly at higher age and are characterized by peripheral cytopenias despite <z:mpath ids='MPATH_458'>normal</z:mpath> or increased cellularity of the bone marrow </plain></SENT>
<SENT sid="1" pm="."><plain>The slowly evolving process of <z:e sem="disease" ids="C0007621" disease_type="Neoplastic Process" abbrv="">neoplastic transformation</z:e> explains the clinical, morphological and prognostic <z:hpo ids='HP_0001425'>heterogeneity</z:hpo> which is not sufficiently addressed even in current classification systems </plain></SENT>
<SENT sid="2" pm="."><plain>In the last decade, considerable progress has been made in dissecting the pathobiology of these complex disorders </plain></SENT>
<SENT sid="3" pm="."><plain>Therapeutic measures have to consider the prognosis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> as well as individual factors of the patient </plain></SENT>
<SENT sid="4" pm="."><plain>Whereas the early stages are treated with supportive care, iron <z:chebi fb="0" ids="38161">chelators</z:chebi>, hematopoietic growth factors and immunomodulatory agents, more advanced cases require the use of demethylating agents and cytotoxic chemotherapy with or without stem cell support </plain></SENT>
<SENT sid="5" pm="."><plain>Allogeneic stem cell transplantation remains the only curative option in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>